Hanol Morihepamin Injection

Adult administration

Generally, 500 mL is administered via infusion. The infusion rate is typically set to more than 180 minutes for 500 mL in adults. When administered through central venous access, 500 mL of this medication is mixed with dextrose solutions and continuously infused over 24 hours in the central vein. The dosage should be adjusted appropriately depending on age, symptoms, and body weight.

This medication must be used according to a doctor's instructions. Do not use in patients with severe renal impairment or high nitrogen levels in the blood, as well as patients with amino acid metabolism disorders beyond liver dysfunction. It should also not be administered to patients with metabolic disorders affecting nitrogen utilization, severe congestive heart failure, or fluid in the lungs. Do not use in patients with very little or no urine output, high sodium and chloride levels in the blood, cardiac conduction disturbances, or myasthenia gravis due to specific components of this medication. Patients who have been excessively supplied with fluids or have had a myocardial infarction, or had a history of myocardial infarction should also avoid this medication. Use with caution in patients with severe acidosis, congestive or severe heart failure, patients with edema due to sodium, patients with high potassium levels or potassium retention, and patients with impaired renal function. This medication contains sodium bisulfite, which may cause allergic reactions or asthma attacks in sensitive patients or asthmatics. Rarely, allergic reactions such as skin rashes may occur, and if such symptoms arise, usage should be discontinued immediately. Gastrointestinal symptoms like nausea or vomiting may occur occasionally, along with chest discomfort, palpitations, rapid heartbeat, or elevated blood pressure. Administering a large volume rapidly can lead to acidosis, so care must be taken. Additionally, symptoms such as chills, fever, headache, difficulty breathing, respiratory arrest, shock, bronchospasm, and urinary cramps may also appear. If magnesium is included, peripheral blood vessels may dilate, leading to decreased blood pressure. There is a risk for metabolic acidosis, hypophosphatemia, alkalosis, hyperglycemia, diabetes, dehydration, rebound hypoglycemia, elevated liver enzymes, vitamin deficiencies or excesses, electrolyte imbalances, and hyperammonemia in children. Patients with poor liver or kidney function may experience elevated blood urea nitrogen (BUN) levels, and those with severely compromised liver function may exhibit serious symptoms such as amino acid imbalance, metabolic alkalosis, systemic nitrogen blood syndrome, hyperammonemia, or coma. Care should be taken regarding electrolyte balance when co-administering with other medications containing electrolytes or during large doses. Overdose can lead to metabolic alkalosis, hence formulations containing acetate ions should be used with caution. In patients with renal disease, pulmonary disease, or severe heart disease, care must be taken to avoid excessive fluid retention. Diabetic patients must frequently monitor their blood glucose levels while using this medication. Patients with hyponatremia, liver failure, or kidney failure should have doses adjusted individually, and hydration balance and serum electrolyte levels must be carefully monitored. This medication may reduce protein synthesis effects when used with certain antibiotics, and if magnesium is included, co-administration with calcium injections may lead to precipitation, so caution is advised. Safety in pregnant women has not been established, so it should only be administered when the benefits outweigh the risks. Children may have immature liver function, so maintain lower dosages, and especially infants should have their blood ammonia levels monitored frequently. Elderly patients may have diminished physiological functions, thus administration rate should be slow and dosage reduced for cautious use. Since this medication contains electrolytes, care must be taken regarding electrolyte balance during high volume administration, and the administration rate should be slowed to prevent side effects like chills or vomiting. When administering, prepare the drug at body temperature and ensure aseptic conditions to reduce the risk of infections. Do not use if the solution is cloudy or discolored, and it should be used within 24 hours if refrigerated. During storage, do not open the packaging, and do not use if the rubber stopper is damaged.

Serious side effects

Hives, severe swelling (edema), difficulty breathing, asthma attacks, chest tightness, difficulty in breathing, pallor, severe edema with elevated blood pressure, liver failure, kidney failure, symptoms related to liver dysfunction (jaundice), serious neurological symptoms (headache, confusion, seizures, etc.) mentioned, shock, bronchospasm, respiratory arrest

Mild side effects

• Nausea
• vomiting
• chest discomfort
• palpitations
• rapid heartbeat (tachycardia)
• elevated blood pressure
• chills
• fever
• headache
• urinary cramping

This medication should be stored in a sealed container to avoid contact with air, kept away from direct sunlight, and stored at room temperature. Proper storage will help maintain the drug's effectiveness and prevent degradation.

Appearance

A colorless to pale yellow transparent solution in a colorless transparent glass vial or in a polypropylene aqueous injection container.

Package unit

100mL/bottle, 200mL/bottle, 250mL/bottle, 500mL/bottle